Lung Cancer Non-small Cell Stage IV Clinical Trial
Official title:
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。
In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03866980 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03769103 -
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
|
Phase 2 | |
| Completed |
NCT02129699 -
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
|
Phase 3 | |
| Recruiting |
NCT05127382 -
Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
|
||
| Completed |
NCT03866993 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04184921 -
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
|